Insulet marked a 13.2% change today, compared to 1.0% for the S&P 500. Is it a good value at today's price of $158.97? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
-
Insulet belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 24.45 and an average price to book (P/B) of 4.16
-
The company's P/B ratio is 18.27
-
Insulet has a trailing 12 month Price to Earnings (P/E) ratio of 176.6 based on its trailing 12 month price to earnings (EPS) of $0.9 per share
-
Its forward P/E ratio is 70.3, based on its forward earnings per share (EPS) of $2.26
-
PODD has a Price to Earnings Growth (PEG) ratio of 2.9, which shows the company is overvalued when we factor growth into the price to earnings calculus.
-
Over the last four years, Insulet has averaged free cash flows of $-64250000.0, which on average grew 3.8%
-
PODD's gross profit margins have averaged 65.2 % over the last four years and during this time they had a growth rate of -1.0 % and a coefficient of variability of 14.4 %.
-
Insulet has moved -49.0% over the last year compared to 16.0% for the S&P 500 -- a difference of -65.0%
-
PODD has an average analyst rating of buy and is -38.37% away from its mean target price of $257.94 per share